SAT0402 SEL-212 PHASE 2 CLINICAL STUDY IN SYMPTOMATIC GOUT PATIENTS: IMMTOR TOLEROGENIC NANOPARTICLES COMBINED WITH PEGADRICASE MITIGATES IMMUNOGENICITY AND ENABLES SUSTAINED REDUCTION OF SERUM URIC ACID LEVELS, LOW RATE OF GOUT FLARES AND MONTHLY DOSING
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.7769
Abstract: Background: Pegylated uricases are promising therapies for the treatment of severe chronic gout, but are limited by their immunogenicity. We have previously shown that ImmTOR tolerogenic nanoparticles (formerly known as SVP-Rapamycin) encapsulating rapamycin co-administered with… read more here.
Keywords: biosciences inc; selecta biosciences; gout; gout flares ... See more keywords
A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141409
Abstract: INTRODUCTION: APTO-253 is the only known small molecule in clinical development to target a conserved G-quadruplex structure in the promoter of the MYC oncogene and interrupt MYC gene expression. In preclinical studies of acute myeloid… read more here.
Keywords: aptose biosciences; inc current; biosciences inc; current equity ... See more keywords